1242273-06-8

Upstream product

• 1242273-00-2 4-fluoro-6,7,8,9-tetrahydro-7-oxo-pyrido[1,2-a]indole-10-acetic acid ethyl ester 
• 1242272-99-6 [4-[3-(2-ethoxy-2-oxoethyl)-7-fluoro-1H-indol-2-yl]-2-oxobutyl]dimethyl-sulfoxonium 
• 1242272-98-5 3-(2-ethoxy-2-oxoethyl)-7-fluoro-1H-indole-2-propanoic acid ethyl ester 
• 1242272-97-4 diethyl 4-[(2-bromo-6-fluorophenyl)imino]heptanedioate 
• 14160-68-0 4,4-diethoxy-heptanedioic acid 1,7-diethyl ester 
• 6317-49-3 4-oxopimelate 
• 133218-06-1 4-fluoro-1-[3-(trimethylsilyl)prop-2-yn-1-yl]benzene 
• 459-46-1 4-Fluorobenzyl bromide 
• 1242273-05-7 (7R)-7-azido-4-fluoro-6,7,8,9-tetrahydro-pyrido[1,2-a]indole-10-acetic acid ethyl ester 
• 70090-68-5 1-fluoro-4-(prop-2-yn-1-yl)benzene 

Downstream Products

• 1242272-15-6 MK-1029 

Relevant academic research and scientific papers

Harnessing the Power of Catalysis for the Synthesis of CRTH2 Antagonist MK-1029

The synthetic strategy utilized to prepare clinical supplies of CRTH2 antagonist MK-1029 is described. Specifically, the approach communicated is predicated on the intervention of five distinct catalytic methods, using three separate metals and an enzyme, to enable successful construction of this complex active pharmaceutical ingredient.

INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS

Compound of formula (I) are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.